Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) FCF Margin (2024 - 2025)

Prelude Therapeutics' FCF Margin history spans 2 years, with the latest figure at 294.08% for Q3 2025.

  • For Q3 2025, FCF Margin rose 61789.0% year-over-year to 294.08%; the TTM value through Dec 2025 reached 867.22%, up 60276.0%, while the annual FY2025 figure was 464.32%, 100565.0% up from the prior year.
  • FCF Margin for Q3 2025 was 294.08% at Prelude Therapeutics, up from 501.08% in the prior quarter.
  • Across five years, FCF Margin topped out at 294.08% in Q3 2025 and bottomed at 911.97% in Q3 2024.